MicroRNAs in the prognosis of triple-negative breast cancer

Lu, Lichong; Mao, Xuhua; Shi, Peiyi; He, Biyu; Xu, Kun; Zhang, Simin; Wang, Jianming

doi:10.1097/md.0000000000007085

Cited by 71 publications

(48 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that a single miRNA can modulate numerous target genes, and >50% of known miRNAs are located at cancer-associated chromosomal regions, suggesting that miRNAs may have crucial roles in tumorigenesis and tumor development (10). Recent studies have revealed the aberrant expression of various miRNAs in breast cancer, and their deregulation has been implicated in breast cancer genesis and development (11)(12)(13). Deregulated miRNAs can have oncogenic or tumor-suppressive roles in breast cancer and control biological behaviors, including cell proliferation, cell cycle, apoptosis, invasion, metastasis, epithelial-mesenchymal transition and angiogenesis (14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway

et al. 2018

View full text Add to dashboard Cite

Numerous studies have revealed that a subset of microRNAs (miRNAs) is aberrantly expressed in breast cancer. The dysregulation of miRNAs is involved in the tumorigenesis and progression of breast cancer due to their negative regulation of downstream target genes. Therefore, the identification of deregulated miRNAs in breast cancer may provide important insights into the diagnosis and treatment of patients with this disease. miRNA-511 (miR-511) has been identified to be deregulated in diverse human cancer types; however, neither the expression status nor the detailed roles of miR-511 in breast cancer have been clarified. Thus, it was aimed to determine the expression of miR-511 in breast cancer, examine the role in malignant progression and explore its downstream targets. The results of the present study revealed that the expression of miR-511 was downregulated in breast cancer tissues and cell lines. Decreased expression of miR-511 was significantly associated with lymph node metastasis and tumor stage in patients with breast cancer. Functional analyses revealed that restoring miR-511 expression suppressed breast cancer cell proliferation and colony formation, promoted apoptosis and reduced metastasis in vitro, while it attenuated tumor growth in vivo. Additionally, it was revealed that SRY-box 9 (SOX9) was a direct target gene of miR-511 in breast cancer cells. SOX9 was upregulated in breast cancer tissues and its expression was inversely correlated with that of miR-511. Furthermore, SOX9 inhibition simulated the tumor-suppressive roles of miR-511 overexpression in breast cancer cells, while SOX9 reintroduction partially rescued these effects of miR-511. Notably, the upregulation of miR-511 targeted SOX9 to deactivate the PI3K/Akt signaling in breast cancer in vitro and in vivo. In conclusion, miR-511 was downregulated in breast cancer, and impeded its malignant progression by directly targeting SOX9 and regulating the PI3K/Akt pathway. Thus, miR-511 is a potential therapeutic target in breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Studies have found that more than half of miRNAs are located in cancer-related genomic regions, suggesting that dysregulation of miRNAs possibly plays key roles in tumour occurrence and progression (12). Increasing number of studies have recently indicated that miRNAs are aberrantly expressed in various types of human cancers, such as lung cancer (13), bladder cancer (14), breast cancer (15) and gastric cancer (16). MiRNAs regulate diverse biological processes, especially those involved in critical pathways linked to cancer cell proliferation, cycle, apoptosis, metastasis, invasion and…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-584 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting MTDH

Zhang

Wang

2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Lung cancer is the third most frequent human malignant tumour and the leading cause of cancer-associated mortality worldwide. Emerging lines of evidence have demonstrated that microRNAs (miRNAs) are upregulated or downregulated in non-small cell lung cancer (NSCLC), and this phenomenon is involved in the regulation of various processes during tumorigenesis and progression, including tumour groWTh, apoptosis, cell invasion, and tumour metastasis. Therefore, understanding the molecular mechanism that associates abnormally expressed miRNAs with NSCLC formation and development may lead to the identification of novel diagnostic, and therapeutic targets for patients with NSCLC. miRNA-584 (miR-584) functions as a tumour suppressor in several types of cancer. However, the expression pattern, detailed biological function and underlying molecular mechanism of miR-584 in NSCLC remain unclear. Therefore, the present study detected the expression of miR-584 in NSCLC, investigated its role in NSCLC cells and determined its underlying molecular mechanism. In the current study, it was demonstrated that miR-584 was downregulated in NSCLC tissues and cell lines. Low miR-584 expression was correlated with tumour size, tumour node metastasis stage and distant metastasis. Overexpression of miR-584 inhibited cell proliferation and invasion in NSCLC. Additionally, metadherin was identified as a direct target gene of miR-584 in NSCLC as confirmed by a series of experiments. Moreover, upregulation of miR-584 was involved in the regulation of the phosphatase and tensin homolog/Akt serine/threonine kinase signalling pathway in NSCLC. Thus, miR-584 may serve as a tumor-suppressor, and the results of the present study provide a reference for future research into the potential mechanisms underlying NSCLC progression.

show abstract

“…72,73 The designed protocol for analysis of lncRNAs in trastuzumab resistance is variable and it is still difficult to understand the importance of each lncRNA in this context, which implies the need for additional studies in this area. regulatory mechanisms in TNBC, 77 more recently lncRNAs were also found to be described in TNBC. 78,79 The first lncRNA with an evidenced role in TNBC was LOC554202.…”

Section: Lncrnas and The Erbb2-overexpression Subtypementioning

confidence: 98%

“…During the past decade, characterization of TNBC was explored at different molecular levels. According to gene expression profiles TNBC was subdivided into six groups, including basal‐1 and ‐2, mesenchymal, mesenchymal stem cell‐like, immune‐modulatory, and enriched androgen pathway; miRNAs are part of important regulatory mechanisms in TNBC, more recently lncRNAs were also found to be described in TNBC …”

Section: Lncrnas and The Triple‐negative Subtypementioning

confidence: 99%

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

et al. 2019

View full text Add to dashboard Cite

Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2 positive and triple negative. Long non‐coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non‐coding RNAs (ncRNAs), including lncRNAs, have been used. In this review, we focus on lncRNAs with differential expression in BC subtypes and how these RNAs may act to contribute to BC heterogeneity. We also emphasize the potential of these lncRNAs as biomarkers.

show abstract

MicroRNAs in the prognosis of triple-negative breast cancer

Cited by 71 publications

References 47 publications

MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway

MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway

MicroRNA-584 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting MTDH

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

Contact Info

Product

Resources

About